Fundamental Analysis of REVANCE THERAPEUTICS INC(NASDAQ:RVNC) stock

Fundamental Rating

RVNC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. RVNC may be in some trouble as it scores bad on both profitability and health. RVNC is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

RVNC had negative earnings in the past year.

RVNC had a negative operating cash flow in the past year.

RVNC had negative earnings in each of the past 5 years.

RVNC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

RVNC has a Return On Assets (-39.96%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-39.96%
ROE	N/A
ROIC	N/A

ROA(3y)-60.64%

ROA(5y)-53.59%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RVNC has a better Gross Margin (72.61%) than 79.69% of its industry peers.

RVNC's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for RVNC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	72.61%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.51%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RVNC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, RVNC has more shares outstanding

RVNC has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, RVNC has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -6.32, we must say that RVNC is in the distress zone and has some risk of bankruptcy.

RVNC has a worse Altman-Z score (-6.32) than 68.23% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-6.32

ROIC/WACCN/A

WACC7.54%

2.3 Liquidity

A Current Ratio of 4.12 indicates that RVNC has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 4.12, RVNC is in line with its industry, outperforming 58.85% of the companies in the same industry.

RVNC has a Quick Ratio of 3.05. This indicates that RVNC is financially healthy and has no problem in meeting its short term obligations.

RVNC's Quick ratio of 3.05 is in line compared to the rest of the industry. RVNC outperforms 54.17% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.12
Quick Ratio	3.05

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

RVNC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.16%, which is quite impressive.

The Revenue has grown by 15.34% in the past year. This is quite good.

RVNC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.20% yearly.

EPS 1Y (TTM)53.16%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%77.3%

Revenue 1Y (TTM)15.34%

Revenue growth 3Y148.24%

Revenue growth 5Y129.2%

Sales Q2Q%110.93%

3.2 Future

The Earnings Per Share is expected to grow by 18.73% on average over the next years. This is quite good.

Based on estimates for the next years, RVNC will show a very strong growth in Revenue. The Revenue will grow by 26.20% on average per year.

EPS Next Y62.05%

EPS Next 2Y35.06%

EPS Next 3Y26.59%

EPS Next 5Y18.73%

Revenue Next Year22.01%

Revenue Next 2Y26.74%

Revenue Next 3Y26.77%

Revenue Next 5Y26.2%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RVNC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year RVNC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RVNC's earnings are expected to grow with 26.59% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.06%

EPS Next 3Y26.59%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RVNC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

REVANCE THERAPEUTICS INC

NASDAQ:RVNC (11/21/2024, 8:00:02 PM)

After market: 3.976 +0.14 (+3.54%)

3.84

+0.04 (+1.05%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap402.82M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-39.96%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	72.61%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.54

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.12
Quick Ratio	3.05
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)53.16%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y62.05%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)15.34%

Revenue growth 3Y148.24%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

REVANCE THERAPEUTICS INC (RVNC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens